Three questions:
1. Does the HA380 cartridge infringe on any of CTSO's patents?
2. Even if it did, would filing a lawsuit against Jafron essentially close the door on the Chinese market, so CTSO would likely just turn a blind eye?
3. If the HA380 provides roughly the same benefits as our cartridge, why did China ask for 2 shipments of our cartridges? Were there just not enough HA380's to go around?
Finally, I'm surprised Dr Ronco replied to your email; good work! But his answer - "My intent is not commercial" - seems to fly in the face of working for/with Cytosorbents. Is he not getting paid by us? Just sounds like he's working with/for a competitor...but maybe in a pandemic like this, these kinds of considerations no longer apply.
Market Data 
Markets 
AI
